Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H25NO3.ClH |
Molecular Weight | 327.846 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1
InChI
InChIKey=DNTDOBSIBZKFCP-YDALLXLXSA-N
InChI=1S/C17H25NO3.ClH/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20;/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3;1H/t12-;/m0./s1
Molecular Formula | C17H25NO3 |
Molecular Weight | 291.3853 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.allergan.com/assets/pdf/betagan_piCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11572462 | https://www.drugs.com/pro/levobunolol.html | https://www.ncbi.nlm.nih.gov/pubmed/3019819 | https://www.ncbi.nlm.nih.gov/pubmed/17459374
Sources: http://www.allergan.com/assets/pdf/betagan_pi
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11572462 | https://www.drugs.com/pro/levobunolol.html | https://www.ncbi.nlm.nih.gov/pubmed/3019819 | https://www.ncbi.nlm.nih.gov/pubmed/17459374
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Levobunolol, sold under the brand name Betagan, has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Levobunolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure cardiogenic shock; or hypersensitivity to any component of these products.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11572462 |
0.76 nM [Ki] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11572462 |
32.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BETAGAN Approved UseBETAGAN ® ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. Launch Date1985 |
|||
Primary | BETAGAN Approved UseBETAGAN ® ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. Launch Date1985 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/336256 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOBUNOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.65 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/336256 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROBUNOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/336256 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOBUNOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/336256 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROBUNOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Short-term effects of topical levobunolol on the human retinal circulation. | 1997 |
|
[Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]. | 1999 Jul |
|
Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface. | 2003 Nov |
|
Metipranolol attenuates lipid peroxidation in rat brain: a comparative study with other antiglaucoma drugs. | 2003 Oct |
|
[Cost-effectivity analysis of the most used antiglaucoma drugs]. | 2004 Aug |
|
Effects of carteolol hydrochloride on the in vitro production of LPS-induced proinflammatory cytokines by murine macrophage. | 2004 Jun |
|
The effect of once-daily levobunolol on intraocular pressure in normal-tension glaucoma. | 2005 Jan-Feb |
|
Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. | 2005 Mar |
|
Daily cost of glaucoma medications in China. | 2007 Oct-Nov |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.allergan.com/assets/pdf/betagan_pi
The recommended starting dose is one to two drops of BETAGAN (Levobunolol) ophthalmic solution 0.5% in the affected eye(s) once a day. Typical dosing with BETAGAN® 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled glaucoma, BETAGAN® 0.5% can be administered b.i.d. As with any new medication, careful monitoring of patients is advised. Dosages above one drop of BETAGAN® 0.5% b.i.d. are not generally more effective.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17459374
The ability of levobunolol to relax ciliary artery rings pre-contracted with other agents, including phenylephrine and in Ca2+-free media was determined by isometric tension recording method. The pre-contraction was maintained for 20 min, then levobunolol was applied every 10 min in a cumulative manner. Levobunolol at 30 mkM and at
100 mkM significantly reduced the contractile response to phenylephrine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:56:51 GMT 2025
by
admin
on
Mon Mar 31 17:56:51 GMT 2025
|
Record UNII |
O90S49LDHH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
||
|
NCI_THESAURUS |
C29705
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB14351MIG
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
6439
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
100000077109
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
DBSALT000251
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
227212
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
O90S49LDHH
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
441415
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
27912-14-7
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
248-725-3
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
O90S49LDHH
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201237
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
759158
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
DTXSID6020777
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
1359801
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
C29153
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | |||
|
m6784
Created by
admin on Mon Mar 31 17:56:51 GMT 2025 , Edited by admin on Mon Mar 31 17:56:51 GMT 2025
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |